---
trial_id: 289
discovery_date: 2022-03-30 22:57:49.217949
date: 2022-03-30 22:57:49.217949
title: "A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis"
summary: |
  <p>EudraCT Number: 2010-020338-25<br />Sponsor Protocol Number: WA25046<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2010-11-02<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BG">BG</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DK">DK</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PL">PL</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020338-25'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2010-020338-25<br />Sponsor Protocol Number: WA25046<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2010-11-02<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BG">BG</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DK">DK</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PL">PL</a> (Ongoing)</p>